Definium Therapeutics, Inc. (NASDAQ:DFTX) Receives Average Recommendation of "Buy" from Analysts

Key Points

• Analysts remain broadly bullish: Eighteen analysts give Definium Therapeutics an average “Buy” rating, with a consensus 12-month price target of $55.00. Recent targets range from $57 at Robert W. Baird to $75 at Piper Sandler.
• The stock has risen sharply but remains volatile: DFTX opened at $46.14, near its 12-month high of $49.70, compared with a low of $8.70. Its beta is 2.23 and market capitalization is approximately $4.60 billion.
• Quarterly results fell short of expectations: The company reported a quarterly loss of $1.44 per share versus the consensus estimate of a $0.55 loss, while insiders have sold roughly $2.17 million of shares over the past 90 days.

Shares of Definium Therapeutics, Inc. (NASDAQ:DFTX - Get Free Report) have been assigned a consensus recommendation of "Buy" from the eighteen analysts that are presently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, fifteen have assigned a buy rating and two have assigned a strong buy rating to the company. The average twelve-month price target among analysts that have updated their coverage on the stock in the last year is $55.00.

A number of research firms recently issued reports on DFTX. Robert W. Baird boosted their target price on shares of Definium Therapeutics from $37.00 to $57.00 and gave the company an "outperform" rating in a research report on Tuesday, June 23rd. Wells Fargo & Company initiated coverage on Definium Therapeutics in a research report on Monday, July 27th. They set an "overweight" rating and a $68.00 price target on the stock. Weiss Ratings reiterated a "sell (d-)" rating on shares of Definium Therapeutics in a research note on Friday, July 17th. Citigroup reiterated a "buy" rating on shares of Definium Therapeutics in a research note on Monday, June 22nd. Finally, Piper Sandler reissued an "overweight" rating and issued a $75.00 price objective (up from $73.00) on shares of Definium Therapeutics in a report on Friday.

Definium Therapeutics Stock Performance

DFTX opened at $46.14 on Friday. Definium Therapeutics has a 12-month low of $8.70 and a 12-month high of $49.70. The company has a current ratio of 4.69, a quick ratio of 4.69 and a debt-to-equity ratio of 0.15. The firm has a market capitalization of $4.60 billion, a PE ratio of -13.45 and a beta of 2.23. The firm has a 50 day moving average of $37.89 and a two-hundred day moving average of $25.87.

Definium Therapeutics (NASDAQ:DFTX - Get Free Report) last released its quarterly earnings data on Thursday, August 6th. The company reported ($1.44) EPS for the quarter, missing the consensus estimate of ($0.55) by ($0.89). On average, analysts anticipate that Definium Therapeutics will post -2.27 EPS for the current year.

Insider Buying and Selling

In other Definium Therapeutics news, insider Mark Sullivan sold 13,008 shares of the company's stock in a transaction that occurred on Thursday, June 25th. The stock was sold at an average price of $45.03, for a total value of $585,750.24. Following the sale, the insider owned 320,571 shares in the company, valued at approximately $14,435,312.13. This represents a 3.90% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, CFO Brandi Roberts sold 3,013 shares of the firm's stock in a transaction that occurred on Thursday, June 25th. The stock was sold at an average price of $45.03, for a total transaction of $135,675.39. Following the sale, the chief financial officer directly owned 209,487 shares in the company, valued at $9,433,199.61. The trade was a 1.42% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 48,096 shares of company stock valued at $2,165,763 in the last ninety days. Insiders own 2.40% of the company's stock.

Institutional Trading of Definium Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the company. Scientech Research LLC acquired a new position in shares of Definium Therapeutics in the third quarter worth about $286,000. Mercer Global Advisors Inc. ADV grew its position in shares of Definium Therapeutics by 10.5% during the 3rd quarter. Mercer Global Advisors Inc. ADV now owns 21,931 shares of the company's stock valued at $259,000 after acquiring an additional 2,079 shares during the period. Virtu Financial LLC acquired a new stake in shares of Definium Therapeutics during the 3rd quarter valued at about $379,000. BNP Paribas Financial Markets increased its stake in shares of Definium Therapeutics by 82.0% in the 3rd quarter. BNP Paribas Financial Markets now owns 15,320 shares of the company's stock valued at $181,000 after purchasing an additional 6,903 shares in the last quarter. Finally, Blair William & Co. IL increased its stake in shares of Definium Therapeutics by 43.6% in the 3rd quarter. Blair William & Co. IL now owns 31,905 shares of the company's stock valued at $376,000 after purchasing an additional 9,687 shares in the last quarter. 27.91% of the stock is owned by hedge funds and other institutional investors.

About Definium Therapeutics

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source